[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516133":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":24,"collaborators":10,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":39,"briefSummary":41,"conditions":42,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":10},{"fullName":5,"class":6},"Institut Paoli-Calmettes","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"collection of blood and tumor samples",null,[12],"Other: blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.","If the patient agrees to take part in the study, he or she will have a blood sample taken from 8 x 4 ml EDTA tubes at the time of inclusion in the trial.Then, at 6 months (+\u002F- 1 month), 1 year and 2 years, the patient will have the same blood sample as at inclusion.If a biopsy is performed as part of routine care, a tumor sample will be taken and sent to the IPC pathology department for FFPE block. If a biopsy is performed and the patient consents, a cystic fluid sample will be taken.",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Dominique GENRE, MD","CONTACT","049122","drci.up@ipc.unicancer.fr",{"type":25,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100516133","early-detection-of-pancreatic-cancer-in-patients-with-papillary-and-mucinous-intracanal-tumours-of-the-pancreas-papillary-and-mucinous-tumours-of-the-pancreas-100516133",false,"NCT06000553","Early Detection of Pancreatic Cancer in Patients With Papillary and Mucinous Intracanal Tumours of the Pancreas Papillary and Mucinous Tumours of the Pancreas","Early Detection of Pancreatic Cancer in Patients With Papillary and Mucinous Intracanal Tumours of the Pancreas Papillary and Mucinous Tumours of the Pancreas PCS-IPMN-IPC 2023-005","Inclusion Criteria:\n\n1. Age over 18\n2. Patient with intermediate-risk or high-risk TIPMP according to the European Study Group on Cystic Tumours of the Pancreas (3)\n3. Signed consent to participate\n4. Affiliation with a social security scheme, or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding woman\n2. Person in an emergency situation or unable to give consent.\n3. Adult subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice),\n4. Unable to undergo medical follow-up for geographical, social or psychological reasons.\n5. contraindication to MRI.","ALL","18 Years",{"count":36,"type":37},360,"ESTIMATED","INTERVENTIONAL",[40],"NA","This trial is a prospective, exploratory and descriptive study. The primary objective is to identify early diagnostic biomarkers in patients with TIPMP based on the analysis of Treg lymphocyte subpopulations and epigenetic signatures, and the secondary objective is to characterize the biological processes underlying the transformation of a pre-neoplastic lesion into established ADPC.",[43],"PAPILLARY AND MUCINOUS INTRACANAL TUMORS OF THE PANCREAS","NOT_YET_RECRUITING","2023-08-17",{"date":47,"type":48},"2023-08-21","ACTUAL",{"date":50,"type":37},"2023-10-30",{"date":52,"type":37},"2028-10-30",{"name":5,"class":6}]